Labetalol S.A.L.F.

Labetalol, the active ingredient in Labetalol S.A.L.F., is a alpha/beta blocker presented as an intravenous solution for intravenous use. It treats hypertensive emergencies and severe hypertension in adult patients.

GNH USA supplies Labetalol S.A.L.F. as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Labetalol is employed in the management of acute elevations in blood pressure within the cardiovascular disease spectrum.

- Hypertensive emergencies: rapid reduction of dangerously high blood pressure to prevent end‑organ damage. - Severe hypertension: controlled lowering of sustained high arterial pressure when oral therapy is insufficient. - Peri‑operative hypertension: stabilization of blood pressure during surgical procedures to reduce cardiovascular risk.

Labetalol may cause a range of adverse reactions, which vary in frequency and severity.

Common Side Effects: - Dizziness: sensation of light‑headedness or imbalance. - Headache: mild to moderate pain in the head region. - Nausea: feeling of queasiness often accompanied by an urge to vomit. - Flushing: transient redness of the skin, especially on the face. - Fatigue: unusual tiredness or lack of energy. - Nasal congestion: blockage or runny nose.

Serious or Rare Side Effects: - Severe hypotension: dangerously low blood pressure requiring immediate intervention. - Bronchospasm: constriction of airway muscles, particularly in patients with asthma. - Hepatic dysfunction: abnormal liver enzyme elevations indicating liver stress. - Heart block: impaired electrical conduction leading to bradycardia. - Arrhythmia: irregular heart rhythm that may be life‑threatening. - Anaphylaxis: acute allergic reaction with potential airway compromise.

Prior to initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential complications.

- Blood pressure monitoring: assess and adjust dosage to avoid excessive hypotension. - Asthma or chronic obstructive pulmonary disease: use cautiously as beta‑blockade may precipitate bronchospasm. - Hepatic impairment: consider dose reduction or increased monitoring of liver function. - Concomitant cardiac conduction disorders: avoid in patients with existing heart block without specialist oversight. - Abrupt discontinuation: taper gradually to prevent rebound hypertension. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Labetalol can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Other antihypertensives (e.g., ACE inhibitors, diuretics): additive blood‑pressure lowering effect may cause severe hypotension. - Calcium channel blockers (especially verapamil): may enhance bradycardia and AV‑node block. - MAO inhibitors: risk of hypertensive crisis when combined. - Insulin or oral hypoglycemics: may mask hypoglycemia symptoms. - Clonidine withdrawal: abrupt cessation can lead to rebound hypertension.

Moderate Interactions (Monitor Closely): - NSAIDs: may reduce antihypertensive effectiveness. - Digitalis glycosides: increased risk of bradyarrhythmias. - Anesthetic agents (e.g., halothane): potential for exaggerated cardiovascular depression. - Diuretics: may potentiate electrolyte disturbances. - Antidepressants (tricyclics): possible additive cardiac effects.